Apparel & Fashion, Gifts & Parts & Components, Household Items, Toys, Packaging, Health & Beauty, Sports & Hobbies Goods, Consumer Electronics, Jewellery, Clocks & Watches.
redispersible polymer powder used for mortar, wall putty, skim coat,tile adhesive
Improved adhesion: Such as walls, ceilings, or wood surfaces. It helps create a strong bond between the putty and the substrate, reducing the risk of cracking or delamination. â??Enhanced workability: It helps achieve a smooth and easy-to-apply consistency, making it easier to fill cracks, level surfaces, and achieve desired finishes. â??Increased flexibility: RDP allowing it to accommodate minor movements or substrate changes without cracking. This is particularly important in areas where some degree of movement is expected, such as walls or ceilings. Improved crack resistance: It enhances the overall strength and durability of the putty, minimizing the risk of cracks forming over time. Water resistance: RDP can reduce the risk of moisture-related issues such as swelling, warping, or degradation.
innovative high-tech company focusing on handheld laser welding solutions. Adhering to the deep professional ability, numerical control system, high-speed transmission system and other core technologies, we are committed to providing high-quality welding solutions to customers in various industries around the world. After decades of development, the company has become a modern high-tech enterprise integrating research and development, sales, production and service. Parameters Working area: 3050x1530 Max. running speed X/Y axis linkage): 150m/min Overall dimension of main machine: 4597x2244x1852 Laser head: 1000-3000W Gear: DESBOER Positioning accuracy: 0.03mm/m Max. acceleration X/Y axis linkage): 1.0G Total weight of machine: 2200kg Machine bed: Tube welding bed Rack: YYC Control system: FRIENDESS Relay: OMRON Repositioning accuracy: 0.02mm/m Table load bearing: 2000kg Laser source: 1000-3000W Gantry structure: High strength aluminum profile Reducer: DESBOER Display size: 21.5 inches Electrical proportional valve: Japan SMC1050-312/2050-312
1.Material: Iron,C45,40Cr,20CrMnTi,42CrMo,Copper,Stainless steel and so on as per your requests. 2.Processing: For 42-Blades Rotavator Gear Box. 3.Heat Treatment Method: Carburizing, Induction, Flame, Nitriding......
1.Material: Iron, C45,40Cr,20CrMnTi,42CrMo, Copper, Stainless steel, and so on as per your requests. 2.Processing: For 46-Blades Rotavator Gear Box. 3.Heat Treatment Method: Carburizing, Induction, Flame, Nitriding......
This is Cherry from Shandong LeKing Machinery Manufacturing CO., LTD. We are a excavator factory in Jining city,Shandong province,China.We can produce both mini hydraulic excavator and Lithium Ion Batteries excavator. Our products have been exported to Indonesia,Philippines, Russia, Malaysia, South Korea, the United States, Brazil, Australia and India and other dozens of countries and regions, products at home and abroad the majority of users trust and praise. BYD brand lithium iron phosphate battery Charge 4 hours, can work 15 hours , energy consumption 1 kilowatt hour per hour
Laser Cutting Machine.
Laser Cutting Machine.
Laser Cutting Machine.
Laser Cutting Machine.
Laser Cutting Machine.
Fiber Laser Cutting Machine.
Fiber Laser Cutting Machine.
Fiber Laser Cutting Machine.
Sample Types : Including Nasopharyngeal swab, Oropharyngeal swab, Sputum Controls : Internal control, UNG enzyme and dUTP used to reduce risk of contamination, false positive and false negative results Product Information Upper and lower respiratory specimens such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate. Authorized Laboratories Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests. About Emergency Use Authorization (EUA) This test (1) has not been FDA cleared or approved, (2) has been authorized by FDA under an EUA for use by authorized laboratories, (3) has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and (4) is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C.360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Indication: Qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider. Emergency use of this test is limited to authorized laboratories. Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests. This letter is in response to your1 request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of your product,2 pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act. Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization. I. Criteria for Issuance of Authorization I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that: 1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus; 2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and, 3. There is no adequate, approved, and available alternative to the emergency use of your product. 4 II. Scope of Authorization I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.
The COVID-19 RT-PCR Detection Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. 263a, to perform high complexity tests. Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper and lower respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infective status. The agent detected may not be the definite cause of disease. Positive results do not rule out bacterial co-infection with other viruses. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. The COVID-19 RT-PCR Detection Kit is intended for use by qualified trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The COVID-19 RT-PCR Detection Kit is only for use under the Food and Drug Administration's Emergency Use Authorization. PRINCIPLE OF DETECTION This product is a fluorescent probe-based Taqman RT-PCR assay system. Firstly, the RNA of SARS-CoV-2 will be reverse transcribed into cDNA by reverse transcriptase, and then PCR amplification will be performed with cDNA as template. During amplification of the template, the TaqMan probe will be degraded due to the 5'-3 polymerase activity and exonuclease activity of Taq DNA polymerase, then the separation of fluorescent reporter and quencher enables the fluorescent signal to be detected by instrument. The ORF1ab gene of SARS-CoV-2 will be detected qualitatively by FAM channel, the N gene of SARS-CoV-2 will be detected qualitatively by JOE channel, the E gene of SARS-CoV-2 will be detected qualitatively by ROX channel, and the internal reference will be detected by CY5 channel. dUTP and UNG enzyme are used in the kit to prevent contamination of the amplified products. Internal reference is used in the kit for quality control starting from sample collection
Face shield PRICE/PC CIF Major ports worldwide USD1.10/pc It consists of a protective cover, foam strip and fixing device made of polymer materials. 2. Nonsterile, single-use. 3. Anti-fog CE/FDA certificates 200/CTN 67.5X44X36 CM 0.1 CBM/CTN 600 ctns, 120,000 pcs / 40'HQ container 280 ctns 56000 pcs in 1x20 container
Second hand clothes.
